| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Customized |
|
Still deciding? Get samples of US$ 170/kg
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| product name | Pimecrolimus |
| CAS NO. | 137071-32-0 |
| Specification | 99% |
| Appearance | white powder |
| Package | 1KG/Bag,5kg/bag,25kg/drum |
| MOQ | 1KG |
| Items | Standards | Results |
| Appearance | White or off-white powder | Complies |
| Identification | By IR | Complies |
| By HPLC | Complies | |
| Specific Optical Rotation | -105.0°~-110.0° | -107.6° |
| Water Content | ≤ 2.00% | 0.60% |
| Heavy Metals | ≤ 20ppm | Complies |
| Residual on Ignition | ≤ 0.10% | 0.06% |
| Related Substances | Impurity A: ≤0.50% | ND |
| Impurity D: ≤0.50% | 0.24% | |
| Impurity C: ≤0.15% | ND | |
| Impurity D: ≤0.50% | 0.15% | |
| Each of Unspecified impurity: ≤0.10% | 0.04% | |
| Total Impurities: ≤1.00% | 0.44% | |
| Assay (HPLC basis on drying) | 98.0%~102.0% | 99.20% |
| Microbial Limit | Total Aerobic: ≤100cfu/g | <10cfu/g |
| Total Yeasts and Molds: ≤100cfu/g | <10cfu/g | |
| Staphylococcus Aureus: Absent | Absent | |
| Pseudomonas Aeruginosa: Absent | Absent | |
| PSD | D50: ≤ 40µm | 12.65µm |
| D90: ≤ 100µm | 42.80µm | |
| Reference Standard | In-house Standard | |
| Conclusion | The product complied to In-house standard. | |
| Storage | Preserve in tight,light-resistant containers in a cool place,at temperature 2ºC~8ºC | |
Pimecrolimus is a semi-synthetic, macrocyclic lactone derived from ascomycin by activation of the 32-hydroxy group with a triflate ester, and nucleophilic substitution with chloride under phase transfer conditions to provide the chloro analogue. Pimecrolimus has been targeted for treatment of inflammatory skin disorders. Like all tacrolimus analogues, pimecrolimus binds to receptor protein, FKBP12. The complex then binds to mTOR preventing it from interacting with target proteins. Pimecrolimus is extensively cited in the literature with over 2,000 citations.
Pimecrolimus is an immunophilin ligand, which binds specifically to the cytosolic receptor, immunophilin macrophilin-12.Target: OthersPimecrolimus blocks T-lymphocyte activation pathway by inhibiting calcineurin function. Pimecrolimus prevents the release of cytokines and pro-inflammatory mediators from mast cells. Pimecrolimus binds to macrophilin-12, the pimecrolimusmacrophilin complex then binds to the cytosolic enzyme calcineurin phosphatase. The pimecrolimus-macrophilin complex prevents the dephosphorylation of the cytoplasmic component of the nuclear factor of activated T cells by inhibiting the action of calcineurin. Pimecrolimus inhibits not only the transcription and synthesis of cytokines from mast cells, but also the release of preformed mediators serotonin and β-hexosaminidase by the inhibition of Fcε-RI-mediated degranulation and secretion.
){kind=link}